Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ADIAL PHARMACEUTICALS, INC.ADIL · Entity 7742 | Director | May 29, 2025 | June 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ADIAL PHARMACEUTICALS, INC.
Report date May 29, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.69 · Expires 2035-05-28 | Direct | 28,000 |
Reported balance
After 2025-05-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-05-29 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 29, 2025 Filed Jun 2, 2025 20:01 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $0.69 | $0.00 |
DisclosureSEC source: 0001213900-25-050020 · ownership.xml · derivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2035-05-28 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 29, 2025. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 22:21 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001213900-24-026724 · ownership.xml · derivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2034-03-24 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing April 25, 2024. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:43 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001213900-23-043121 · ownership.xml · derivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-05-23 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing May 23, 2023. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 19:57 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001213900-22-009425 · ownership.xml · derivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-02-22 F1 · shares: The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months commencing March 23, 2022. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 15:39 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 10,000 | $2.71 | $27,100.00 |
DisclosureSEC source: 0001213900-22-000067 · ownership.xml · nonDerivative · entry 6 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Roth IRA FBO James W Newman, Jr. Disclosed balance after: 34,644 F6 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transaction at prices ranging from $2.655 to $2.72, inclusive. F8 · ownership.nature: Courtney Newman is the daughter of James W. Newman, Jr. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 15:39 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 5,000 | $2.72 | $13,600.00 |
DisclosureSEC source: 0001213900-22-000067 · ownership.xml · nonDerivative · entry 5 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 50,221 F5 · ownership.nature: James W. Newman is the general partner of Ivy Cottage Group, LLC. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 15:39 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 10,000 | $2.66 | $26,600.00 |
DisclosureSEC source: 0001213900-22-000067 · ownership.xml · nonDerivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transaction at prices ranging from $2.628 to $2.68, inclusive. The reporting person undertakes to provide Adial Pharmaceuticals, Inc., any security holder of Adial Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (6) of this Form 4. Read SEC document |
| November 26, 2021 Filed Nov 30, 2021 14:25 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 10,000 | $2.85 | $28,500.00 |
DisclosureSEC source: 0001213900-21-062465 · ownership.xml · nonDerivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Rountop Limited Partnership, LLP Disclosed balance after: 34,475 F1 · ownership.nature: James W. Newman, Jr. is the general partner of Roundtop Limited Partnership, LLP. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:54 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option · Derivative | 40,000 | $0.00 Strike: $3.11 | $0.00 |
DisclosureSEC source: 0001213900-21-008165 · ownership.xml · derivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-02-07 F1 · shares: The option vests pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:44 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 2,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-005041 · ownership.xml · nonDerivative · entry 4 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Virga Ventures, LLC Disclosed balance after: 152,963 F1 · price: The reporting person acquired an aggregate of 3,731 shares of issuer common stock in exchange for an aggregate 0.53% interest in Purnovate, LLC ("Purnovate") pursuant to Purnovate's merger into a wholly owned subsidiary of the issuer, as contemplated by that certain Equity Purchase Agreement, dated December 7, 2020, as amended. The shares issued to the reporting person in the merger are currently being held in escrow and 70% of the shares are subject to forfeiture during a one year period following the merger to satisfy claims arising as a result of Purnovate's breach of any of its representations and warranties or covenants in the purchase agreement. F4 · ownership.nature: James W. Newman is the sole member of Virga Ventures, LLC. Read SEC document |
| January 26, 2021 Filed Jan 29, 2021 00:44 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantCommon Stock | 1,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-21-005041 · ownership.xml · nonDerivative · entry 2 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Roundtop Limited Partnership, LLP Disclosed balance after: 14,475 F1 · shares: The reporting person acquired an aggregate of 3,731 shares of issuer common stock in exchange for an aggregate 0.53% interest in Purnovate, LLC ("Purnovate") pursuant to Purnovate's merger into a wholly owned subsidiary of the issuer, as contemplated by that certain Equity Purchase Agreement, dated December 7, 2020, as amended. The shares issued to the reporting person in the merger are currently being held in escrow and 70% of the shares are subject to forfeiture during a one year period following the merger to satisfy claims arising as a result of Purnovate's breach of any of its representations and warranties or covenants in the purchase agreement. F1 · price: The reporting person acquired an aggregate of 3,731 shares of issuer common stock in exchange for an aggregate 0.53% interest in Purnovate, LLC ("Purnovate") pursuant to Purnovate's merger into a wholly owned subsidiary of the issuer, as contemplated by that certain Equity Purchase Agreement, dated December 7, 2020, as amended. The shares issued to the reporting person in the merger are currently being held in escrow and 70% of the shares are subject to forfeiture during a one year period following the merger to satisfy claims arising as a result of Purnovate's breach of any of its representations and warranties or covenants in the purchase agreement. F2 · ownership.nature: James W. Newman is the general partner of Roundtop Limited Partnership, LLP. Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 13:23 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 4,644 | $1.35 | $6,269.40 |
DisclosureSEC source: 0001213900-20-007845 · ownership.xml · nonDerivative · entry 6 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Roth IRA FBO James W Newman, Jr. Disclosed balance after: 14,644 F5 · ownership.nature: James W. Newman is the beneficiary of this Roth IRA. Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 13:23 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 10,000 | $1.34 | $13,400.00 |
DisclosureSEC source: 0001213900-20-007845 · ownership.xml · nonDerivative · entry 2 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Roundtop Limited Partnership, LLP Disclosed balance after: 13,288 F1 · shares: James W. Newman is the general partner of Roundtop Limited Partnership, LLP. F1 · price: James W. Newman is the general partner of Roundtop Limited Partnership, LLP. F1 · ownership.nature: James W. Newman is the general partner of Roundtop Limited Partnership, LLP. Read SEC document |
| March 27, 2020 Filed Mar 30, 2020 13:23 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 5,000 | $1.42 | $7,100.00 |
DisclosureSEC source: 0001213900-20-007845 · ownership.xml · nonDerivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| March 03, 2020 Filed Mar 6, 2020 00:19 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | GrantStock Option · Derivative | 60,000 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001213900-20-005541 · ownership.xml · derivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2030-03-02 F1 · shares: The option vests pro rata on a monthly basis over 36 months. F1 · derivative.exercise_date: The option vests pro rata on a monthly basis over 36 months. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 23:47 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 92,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-015554 · ownership.xml · derivative · entry 6 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Virga Ventures LLC Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2023-07-31 F2 · shares: On November 12, 2018, Virga Ventures, LLC exchanged a warrant to purchase 92,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 92,000 shares of common stock. Mr. Newman is the sole member of Virga Ventures, LLC. F2 · price: On November 12, 2018, Virga Ventures, LLC exchanged a warrant to purchase 92,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 92,000 shares of common stock. Mr. Newman is the sole member of Virga Ventures, LLC. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 23:47 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 92,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-18-015554 · ownership.xml · derivative · entry 5 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Virga Ventures LLC Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2023-07-31 F2 · shares: On November 12, 2018, Virga Ventures, LLC exchanged a warrant to purchase 92,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 92,000 shares of common stock. Mr. Newman is the sole member of Virga Ventures, LLC. F2 · price: On November 12, 2018, Virga Ventures, LLC exchanged a warrant to purchase 92,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 92,000 shares of common stock. Mr. Newman is the sole member of Virga Ventures, LLC. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 23:47 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase units · Derivative | 92,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-18-015554 · ownership.xml · derivative · entry 4 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Owned by Virga Ventures LLC Disclosed balance after: 0 Underlying: Units · 184,000 shares Expires 2023-07-31 F2 · shares: On November 12, 2018, Virga Ventures, LLC exchanged a warrant to purchase 92,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 92,000 shares of common stock. Mr. Newman is the sole member of Virga Ventures, LLC. F2 · price: On November 12, 2018, Virga Ventures, LLC exchanged a warrant to purchase 92,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 92,000 shares of common stock. Mr. Newman is the sole member of Virga Ventures, LLC. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 23:47 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 20,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-015554 · ownership.xml · derivative · entry 3 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-07-31 F1 · shares: On November 12, 2018, Ivy Cottage Group, LLC exchanged a warrant to purchase 20,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 20,000 shares of common stock. Mr. Newman is the general partner of Ivy Cottage Group, LLC. F1 · price: On November 12, 2018, Ivy Cottage Group, LLC exchanged a warrant to purchase 20,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 20,000 shares of common stock. Mr. Newman is the general partner of Ivy Cottage Group, LLC. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 23:47 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 20,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-18-015554 · ownership.xml · derivative · entry 2 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2023-07-31 F1 · shares: On November 12, 2018, Ivy Cottage Group, LLC exchanged a warrant to purchase 20,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 20,000 shares of common stock. Mr. Newman is the general partner of Ivy Cottage Group, LLC. F1 · price: On November 12, 2018, Ivy Cottage Group, LLC exchanged a warrant to purchase 20,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 20,000 shares of common stock. Mr. Newman is the general partner of Ivy Cottage Group, LLC. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 23:47 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase units · Derivative | 20,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-18-015554 · ownership.xml · derivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 0 Underlying: Units · 40,000 shares Expires 2023-07-31 F1 · shares: On November 12, 2018, Ivy Cottage Group, LLC exchanged a warrant to purchase 20,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 20,000 shares of common stock. Mr. Newman is the general partner of Ivy Cottage Group, LLC. F1 · price: On November 12, 2018, Ivy Cottage Group, LLC exchanged a warrant to purchase 20,000 units, each unit consisting of a share of common stock and a warrant to purchase a share of common stock, for two separate warrants to purchase 20,000 shares of common stock. Mr. Newman is the general partner of Ivy Cottage Group, LLC. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseWarrant to purchase common stock · Derivative | 10,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 20 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2023-07-31 F13 · shares: On July 31, 2018, James W. Newman Jr. Roth IRA purchased 10,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F13 · price: On July 31, 2018, James W. Newman Jr. Roth IRA purchased 10,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F14 · ownership.direct: Shares are held by the James W. Newman Jr. Roth IRA. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseWarrant to purchase common stock · Derivative | 10,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 19 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Virga Ventures LLC Disclosed balance after: 102,000 Underlying: Common Stock · 10,000 shares Expires 2023-07-31 F12 · shares: On July 31, 2018, Virga Ventures LLC purchased 10,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F12 · price: On July 31, 2018, Virga Ventures LLC purchased 10,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase units · Derivative | 92,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 18 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Virga Ventures LLC Disclosed balance after: 92,000 Underlying: Units · 184,000 shares Expires 2023-07-31 F10 · shares: The warrant to purchase 92,000 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 184,000 shares. F10 · price: The warrant to purchase 92,000 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 184,000 shares. F10 · derivative.underlying: The warrant to purchase 92,000 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 184,000 shares. F4 · ownership.nature: James W. Newman is the sole member of Virga Ventures, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase units · Derivative | 20,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 17 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 20,000 Underlying: Units · 40,000 shares Expires 2023-07-31 F9 · shares: The warrant to purchase 20,000 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 40,000 shares. F9 · price: The warrant to purchase 20,000 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 40,000 shares. F9 · derivative.underlying: The warrant to purchase 20,000 units was received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. Each unit consisted of a share of common stock and a warrant to purchase a share of common stock. The aggregate number of shares of common stock included in the units and underlying the warrants included in the units is 40,000 shares. F6 · ownership.nature: James W. Newman is the general partner of Ivy Cottage Group, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 92,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 16 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Virga Ventures LLC Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2023-07-31 F8 · shares: The 92,000 shares of common stock and warrants to purchase 92,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F8 · price: The 92,000 shares of common stock and warrants to purchase 92,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F4 · ownership.nature: James W. Newman is the sole member of Virga Ventures, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 20,000 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 15 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 25,178 Underlying: Common Stock · 20,000 shares Expires 2023-07-31 F7 · shares: The 20,000 shares of common stock and warrants to purchase 20,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F7 · price: The 20,000 shares of common stock and warrants to purchase 20,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F6 · ownership.nature: James W. Newman is the general partner of Ivy Cottage Group, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 5,178 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 14 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 5,178 Underlying: Common Stock · 5,178 shares Expires 2023-07-31 F5 · price: The 5,178 shares of common stock and a warrant to purchase 5,178 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $1,729.95 at a conversion price of $0.44 per share upon consummation of the initial public offering. F6 · ownership.nature: James W. Newman is the general partner of Ivy Cottage Group, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 21,715 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 13 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Virga Ventures LLC Disclosed balance after: 21,715 Underlying: Common Stock · 21,715 shares Expires 2023-07-31 F3 · price: The 21,715 shares of common stock and a warrant to purchase 21,715 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $7,255.02 at a conversion price of $0.44 per share upon consummation of the initial public offering. F4 · ownership.nature: James W. Newman is the sole member of Virga Ventures, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherWarrant to purchase common stock · Derivative | 29,931 | Not disclosed Strike: $6.25 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 12 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Newman GST Trust FBO James W. Newman Jr. Disclosed balance after: 29,931 Underlying: Common Stock · 29,931 shares Expires 2023-07-31 F1 · security: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · price: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F2 · ownership.nature: James W. Newman is the trustee of the Newman GST Trust FBO James W. Neman Jr. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionConvertible Note · Derivative | 5,178 | Not disclosed Strike: $0.44 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 11 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 0 Underlying: Common Stock · 5,178 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The 5,178 shares of common stock and a warrant to purchase 5,178 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $1,729.95 at a conversion price of $0.44 per share upon consummation of the initial public offering. F5 · derivative.exercise_date: The 5,178 shares of common stock and a warrant to purchase 5,178 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $1,729.95 at a conversion price of $0.44 per share upon consummation of the initial public offering. F5 · derivative.expiration_date: The 5,178 shares of common stock and a warrant to purchase 5,178 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $1,729.95 at a conversion price of $0.44 per share upon consummation of the initial public offering. F6 · ownership.nature: James W. Newman is the general partner of Ivy Cottage Group, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionConvertible Note · Derivative | 21,715 | Not disclosed Strike: $0.44 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 10 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Virga Ventures LLC Disclosed balance after: 0 Underlying: Common Stock · 21,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The 21,715 shares of common stock and a warrant to purchase 21,715 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $7,255.02 at a conversion price of $0.44 per share upon consummation of the initial public offering. F3 · derivative.exercise_date: The 21,715 shares of common stock and a warrant to purchase 21,715 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $7,255.02 at a conversion price of $0.44 per share upon consummation of the initial public offering. F3 · derivative.expiration_date: The 21,715 shares of common stock and a warrant to purchase 21,715 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $7,255.02 at a conversion price of $0.44 per share upon consummation of the initial public offering. F4 · ownership.nature: James W. Newman is the sole member of Virga Ventures, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionConvertible Note · Derivative | 29,931 | Not disclosed Strike: $0.44 | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · derivative · entry 9 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Newman GST Trust FBO James W. Newman Jr. Disclosed balance after: 0 Underlying: Common Stock · 29,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · derivative.exercise_date: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · derivative.expiration_date: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F2 · ownership.nature: James W. Newman is the trustee of the Newman GST Trust FBO James W. Neman Jr. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · nonDerivative · entry 7 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F13 · shares: On July 31, 2018, James W. Newman Jr. Roth IRA purchased 10,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F13 · price: On July 31, 2018, James W. Newman Jr. Roth IRA purchased 10,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F14 · ownership.direct: Shares are held by the James W. Newman Jr. Roth IRA. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | PurchaseCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · nonDerivative · entry 6 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Virga Ventures, LLC Disclosed balance after: 150,419 F12 · shares: On July 31, 2018, Virga Ventures LLC purchased 10,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. F12 · price: On July 31, 2018, Virga Ventures LLC purchased 10,000 units (the "Units") in the initial public offering at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant. Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the initial public offering. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherCommon Stock | 92,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · nonDerivative · entry 5 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Virga Ventures, LLC Disclosed balance after: 140,419 F8 · shares: The 92,000 shares of common stock and warrants to purchase 92,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F8 · price: The 92,000 shares of common stock and warrants to purchase 92,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F4 · ownership.nature: James W. Newman is the sole member of Virga Ventures, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | OtherCommon Stock | 20,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · nonDerivative · entry 4 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 35,094 F7 · shares: The 20,000 shares of common stock and warrants to purchase 20,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F7 · price: The 20,000 shares of common stock and warrants to purchase 20,000 shares of common stock were received by the reporting person upon consummation of the initial public offering in accordance with a Securities Purchase Agreement dated February 22, 2018. F6 · ownership.nature: James W. Newman is the general partner of Ivy Cottage Group, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionCommon Stock | 5,178 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · nonDerivative · entry 3 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Ivy Cottage Group, LLC Disclosed balance after: 15,221 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · shares: The 5,178 shares of common stock and a warrant to purchase 5,178 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $1,729.95 at a conversion price of $0.44 per share upon consummation of the initial public offering. F5 · price: The 5,178 shares of common stock and a warrant to purchase 5,178 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $1,729.95 at a conversion price of $0.44 per share upon consummation of the initial public offering. F6 · ownership.nature: James W. Newman is the general partner of Ivy Cottage Group, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionCommon Stock | 21,715 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · nonDerivative · entry 2 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Virga Ventures, LLC Disclosed balance after: 58,419 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The 21,715 shares of common stock and a warrant to purchase 21,715 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $7,255.02 at a conversion price of $0.44 per share upon consummation of the initial public offering. F3 · price: The 21,715 shares of common stock and a warrant to purchase 21,715 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $7,255.02 at a conversion price of $0.44 per share upon consummation of the initial public offering. F4 · ownership.nature: James W. Newman is the sole member of Virga Ventures, LLC Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 20:10 UTC | ADIAL PHARMACEUTICALS, INC. ADIL · Entity 7742 | ConversionCommon Stock | 29,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-18-010089 · ownership.xml · nonDerivative · entry 1 Newman James W. Jr. · CIK 0001718364 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Newman GST Trust FBO James W. Newman Jr. Disclosed balance after: 41,160 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F1 · price: The 29,931 shares of common stock and a warrant to purchase 29,931 shares of common stock were issued upon automatic conversion of a convertible note in the principal amount of $10,000 together with accrued interest thereon at a conversion price of $0.44 per share upon consummation of the initial public offering on July 31, 2018. F2 · ownership.nature: James W. Newman is the trustee of the Newman GST Trust FBO James W. Neman Jr. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.